FD 594
Latest Information Update: 08 Nov 2006
Price :
$50 *
At a glance
- Originator Taisho Pharmaceutical
- Class Cytostatic antibiotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Cancer
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Bacterial infections in Japan (unspecified route)
- 08 Nov 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 26 Jul 2001 No-Development-Reported for Bacterial infections in Japan (Unknown route)